172 related articles for article (PubMed ID: 37755632)
1. Characterizing T-cell dysfunction and exclusion signatures in malignant peripheral nerve sheath tumors reveals susceptibilities to immunotherapy.
Bhandarkar AR; Bhandarkar S; Babovic-Vuksanovic D; Parney IF; Spinner RJ
J Neurooncol; 2023 Sep; 164(3):693-699. PubMed ID: 37755632
[TBL] [Abstract][Full Text] [Related]
2. STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.
Somatilaka BN; Madana L; Sadek A; Chen Z; Chandrasekaran S; McKay RM; Le LQ
J Clin Invest; 2024 Mar; 134(10):. PubMed ID: 38502231
[TBL] [Abstract][Full Text] [Related]
3. Malignant peripheral nerve sheath tumor: models, biology, and translation.
Somatilaka BN; Sadek A; McKay RM; Le LQ
Oncogene; 2022 Apr; 41(17):2405-2421. PubMed ID: 35393544
[TBL] [Abstract][Full Text] [Related]
4. Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
Hirbe AC; Kaushal M; Sharma MK; Dahiya S; Pekmezci M; Perry A; Gutmann DH
Cancer; 2017 Apr; 123(7):1194-1201. PubMed ID: 27875628
[TBL] [Abstract][Full Text] [Related]
5. Patterns of recurrence and survival in sporadic, neurofibromatosis Type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors.
Watson KL; Al Sannaa GA; Kivlin CM; Ingram DR; Landers SM; Roland CL; Cormier JN; Hunt KK; Feig BW; Ashleigh Guadagnolo B; Bishop AJ; Wang WL; Slopis JM; McCutcheon IE; Lazar AJ; Torres KE
J Neurosurg; 2017 Jan; 126(1):319-329. PubMed ID: 27035165
[TBL] [Abstract][Full Text] [Related]
6. Circulating tumor DNA for malignant peripheral nerve sheath tumors in neurofibromatosis type 1.
Jones J; Cain S; Pesic-Smith J; Choong PFM; Morokoff AP; Drummond KJ; Dabscheck G
J Neurooncol; 2021 Sep; 154(3):265-274. PubMed ID: 34529228
[TBL] [Abstract][Full Text] [Related]
7. Survival outcomes of malignant peripheral nerve sheath tumors (MPNSTs) with and without neurofibromatosis type I (NF1): a meta-analysis.
Lim Z; Gu TY; Tai BC; Puhaindran ME
World J Surg Oncol; 2024 Jan; 22(1):14. PubMed ID: 38191386
[TBL] [Abstract][Full Text] [Related]
8. Microarray-based copy number analysis of neurofibromatosis type-1 (NF1)-associated malignant peripheral nerve sheath tumors reveals a role for Rho-GTPase pathway genes in NF1 tumorigenesis.
Upadhyaya M; Spurlock G; Thomas L; Thomas NS; Richards M; Mautner VF; Cooper DN; Guha A; Yan J
Hum Mutat; 2012 Apr; 33(4):763-76. PubMed ID: 22331697
[TBL] [Abstract][Full Text] [Related]
9. NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
Park HJ; Lee SJ; Sohn YB; Jin HS; Han JH; Kim YB; Yim H; Jeong SY
Int J Oncol; 2013 Feb; 42(2):657-66. PubMed ID: 23292448
[TBL] [Abstract][Full Text] [Related]
10. Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1-associated atypical neurofibromas.
Pemov A; Hansen NF; Sindiri S; Patidar R; Higham CS; Dombi E; Miettinen MM; Fetsch P; Brems H; Chandrasekharappa SC; Jones K; Zhu B; Wei JS; ; ; Mullikin JC; Wallace MR; Khan J; Legius E; Widemann BC; Stewart DR
Neuro Oncol; 2019 Aug; 21(8):981-992. PubMed ID: 30722027
[TBL] [Abstract][Full Text] [Related]
11. A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.
Fernández-Rodríguez J; Creus-Bachiller E; Zhang X; Martínez-Iniesta M; Ortega-Bertran S; Guha R; Thomas CJ; Wallace MR; Romagosa C; Salazar-Huayna L; Reilly KM; Blakely JO; Serra-Musach J; Pujana MA; Serra E; Villanueva A; Ferrer M; Lázaro C
Mol Cancer Ther; 2022 Jul; 21(7):1246-1258. PubMed ID: 35511749
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of magnetic resonance imaging-based radiomics characteristics for differentiation of benign and malignant peripheral nerve sheath tumors in neurofibromatosis type 1.
Ristow I; Madesta F; Well L; Shenas F; Wright F; Molwitz I; Farschtschi S; Bannas P; Adam G; Mautner VF; Werner R; Salamon J
Neuro Oncol; 2022 Oct; 24(10):1790-1798. PubMed ID: 35426432
[TBL] [Abstract][Full Text] [Related]
13. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
Varin J; Poulain L; Hivelin M; Nusbaum P; Hubas A; Laurendeau I; Lantieri L; Wolkenstein P; Vidaud M; Pasmant E; Chapuis N; Parfait B
Oncotarget; 2016 Jun; 7(24):35753-35767. PubMed ID: 26840085
[TBL] [Abstract][Full Text] [Related]
14. Transcriptomic subtyping of malignant peripheral nerve sheath tumours highlights immune signatures, genomic profiles, patient survival and therapeutic targets.
Høland M; Berg KCG; Eilertsen IA; Bjerkehagen B; Kolberg M; Boye K; Lingjærde OC; Guren TK; Mandahl N; van den Berg E; Palmerini E; Smeland S; Picci P; Mertens F; Sveen A; Lothe RA
EBioMedicine; 2023 Nov; 97():104829. PubMed ID: 37837931
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive adipocytic and neurogenic tissue microarray analysis of NY-ESO-1 expression - a promising immunotherapy target in malignant peripheral nerve sheath tumor and liposarcoma.
Shurell E; Vergara-Lluri ME; Li Y; Crompton JG; Singh A; Bernthal N; Wu H; Eilber FC; Dry SM
Oncotarget; 2016 Nov; 7(45):72860-72867. PubMed ID: 27655679
[TBL] [Abstract][Full Text] [Related]
16. Confirmation of mutation landscape of NF1-associated malignant peripheral nerve sheath tumors.
Sohier P; Luscan A; Lloyd A; Ashelford K; Laurendeau I; Briand-Suleau A; Vidaud D; Ortonne N; Pasmant E; Upadhyaya M
Genes Chromosomes Cancer; 2017 May; 56(5):421-426. PubMed ID: 28124441
[TBL] [Abstract][Full Text] [Related]
17. VEGF and VEGFR family members are expressed by neoplastic cells of NF1-associated tumors and may play an oncogenic role in malignant peripheral nerve sheath tumor growth through an autocrine loop.
Bonsang B; Maksimovic L; Maille P; Martin N; Laurendeau I; Pasmant E; Bièche I; Deschamps J; Wolkenstein P; Ortonne N
Ann Diagn Pathol; 2022 Oct; 60():151997. PubMed ID: 35777330
[TBL] [Abstract][Full Text] [Related]
18. FOXM1 promotes neurofibromatosis type 1-associated malignant peripheral nerve sheath tumor progression in a NUF2-dependent manner.
Aimaier R; Chung MH; Gu Y; Yu Q; Wei C; Li H; Guo Z; Long M; Li Y; Wang W; Li Q; Wang Z
Cancer Gene Ther; 2023 Oct; 30(10):1390-1402. PubMed ID: 37488294
[TBL] [Abstract][Full Text] [Related]
19. RRM2 as a novel prognostic and therapeutic target of NF1-associated MPNST.
Chung MH; Aimaier R; Yu Q; Li H; Li Y; Wei C; Gu Y; Wang W; Guo Z; Long M; Li Q; Wang Z
Cell Oncol (Dordr); 2023 Oct; 46(5):1399-1413. PubMed ID: 37086345
[TBL] [Abstract][Full Text] [Related]
20. High-resolution DNA copy number profiling of malignant peripheral nerve sheath tumors using targeted microarray-based comparative genomic hybridization.
Mantripragada KK; Spurlock G; Kluwe L; Chuzhanova N; Ferner RE; Frayling IM; Dumanski JP; Guha A; Mautner V; Upadhyaya M
Clin Cancer Res; 2008 Feb; 14(4):1015-24. PubMed ID: 18281533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
